virus
oblig
cellular
parasit
therefor
surpris
virus
share
similar
metabol
strategi
host
mani
import
function
virus
either
encod
protein
close
relat
host
protein
evolv
abil
directli
coopt
servic
cellular
factor
date
although
mani
viral
infect
success
prevent
via
vaccin
lack
effect
knowledg
vaccin
numer
import
human
pathogen
includ
hepat
c
viru
hcv
human
immunodefici
viru
hiv
accordingli
antivir
drug
like
remain
signific
mainstay
treat
mani
viral
diseas
regrett
medic
licens
antivir
current
number
less
nevertheless
repres
substanti
progress
year
ago
fewer
five
antivir
clinic
use
target
host
viru
consid
design
antivir
drug
one
envis
two
broad
strategi
virus
replic
use
selfencod
protein
seiz
control
cellular
factor
agent
design
interrupt
viral
replic
could
principl
target
equal
effect
either
viral
cellular
interestingli
two
strategi
hold
differ
implic
case
uniqu
viral
function
capsid
format
lower
risk
creat
inhibitor
toxic
effect
host
similar
advantag
antibacteri
drug
inhibit
bacteri
target
exist
host
case
target
viral
helicas
smaller
window
specif
viral
cellular
enzym
catalys
similar
enzymat
reaction
howev
viral
cellular
enzym
ident
tradit
medicin
chemistri
structurebas
drug
design
exploit
differ
host
viral
enzym
creat
drug
high
specif
viru
achil
heel
antivir
therapi
unless
drug
incred
potent
reduc
size
replic
pool
viru
rapidli
therefor
requir
short
durat
treatment
reduc
time
resist
virus
amplifi
resist
treatment
aris
time
observ
hiv
hbv
patient
therapi
target
cellular
factor
requir
viral
replic
help
overcom
problem
viral
resist
theoret
drug
could
panantivir
inhibit
virus
depend
host
factor
oper
defin
panantivir
mean
inhibitor
target
one
famili
virus
latter
intervent
strategi
limit
develop
resist
virus
major
disadvantag
gener
caus
greater
toxic
host
empir
one
focus
one
antivir
drug
design
influenc
whether
viru
replic
larg
autonom
host
use
predominantli
viral
encod
gene
exampl
herp
simplex
viru
hsv
whether
viru
intim
associ
host
metabol
exampl
integr
provirus
review
discuss
nonexhaust
fashion
hcvencod
helicas
cellular
helicas
adopt
use
two
illustr
exampl
potenti
antivir
target
helicas
motif
structur
function
basic
level
helicas
motor
enzym
use
energi
deriv
ntp
hydrolysi
unwind
doublestrand
nucleic
classif
depend
whether
helicas
bind
singlestrand
nucleic
acid
unwind
rna
dna
direct
unwind
whether
certain
signatur
motif
present
primari
sequenc
helicas
divid
three
superfamili
two
small
famili
base
sequenc
comparison
conserv
exampl
member
shown
tabl
figur
show
schemat
illustr
seven
highli
conserv
motif
among
two
largest
famili
although
discuss
later
conserv
motif
associ
conserv
helicas
function
comparison
primari
sequenc
two
helicas
fig
hcv
helicas
human
reveal
pauciti
ident
residu
highlight
green
tremend
diverg
sequenc
outsid
conserv
motif
highlight
red
differ
primari
sequenc
tertiari
structur
helicas
viral
pathogen
cellular
helicas
exploit
confer
specif
antivir
inhibitor
structur
number
helicas
solv
recent
review
helicas
structur
function
total
number
domain
vari
four
pcrarep
three
hcv
helicas
two
elong
initi
factor
differ
domain
threedomain
helicas
hcv
helicas
shown
schemat
fig
domain
magenta
domain
yellow
domain
cyan
clearli
delin
domain
form
core
conserv
helicas
contain
conserv
sequenc
motif
interfac
two
domain
seen
exampl
hcv
helicas
fig
surprisingli
despit
wide
dispar
protein
sequenc
similar
structur
element
conserv
structur
solv
date
illustr
overlay
structur
hcv
rna
red
three
domain
pcra
dna
cyan
four
domain
fig
posit
length
number
orient
core
enzym
top
two
domain
similar
contrast
diverg
clearli
seen
domain
bottom
left
hcv
helicas
counterpart
domain
pcra
helicas
cyan
bottom
right
helicas
bind
ntp
use
two
structur
element
phosphatebind
ploop
also
known
motif
iwalk
motif
motif
ii
cofactorbind
loop
also
known
walker
rna
helicas
also
call
dea
dh
box
helicas
signatur
sequenc
walker
b
motif
highlight
orang
fig
residu
conserv
motif
requir
bind
hydrolys
ntp
lie
interfac
domain
hcv
helicas
consider
flexibl
distanc
two
domain
although
ntp
hydrolysi
occur
domain
close
configur
addit
crystallograph
mutat
analys
identifi
motif
contribut
oligonucleotid
bind
ia
txgx
motif
span
bottom
cleft
domain
act
hing
movement
domain
exact
chang
physic
conform
path
rna
dna
take
one
strand
destabil
unwound
well
understood
seem
conserv
differ
helicas
complic
matter
helicas
seem
function
monom
exampl
hcv
helicas
other
dimer
exampl
hsv
yet
other
hexam
exampl
simian
viru
antigen
mani
put
helicas
far
identifi
presenc
deadh
box
primari
sequenc
await
biochem
verif
bona
fide
helicas
function
howev
crucial
element
helicas
function
detect
primari
sequenc
structur
analys
identifi
crucial
residu
conserv
space
primari
sequenc
exampl
shown
fig
crystal
structur
interfac
domain
left
right
hcv
green
pcra
blue
superimpos
two
pair
arginin
residu
inner
face
domain
highlight
circl
shown
mutat
analys
essenti
ntp
hydrolysi
lower
pair
pcra
yellow
stick
hcv
helicas
white
stick
motif
vi
structur
function
homolog
upper
pair
hcv
helicas
also
show
close
function
structur
homolog
pcra
deriv
two
differ
sequenc
motif
hcv
residu
pair
encod
motif
vi
wherea
analog
pcra
residu
come
motif
iv
relationship
deriv
homolog
search
sequenc
cellular
function
rna
helicas
dead
protein
numer
member
helicas
superfamili
tabl
ubiquit
eukaryot
genom
shown
fig
although
precis
substrat
remain
undefin
dead
helicas
involv
pleiotrop
mani
aspect
rna
metabol
includ
transcript
mrna
splice
mrna
export
translat
rna
stabil
mitochondri
gene
despit
larg
number
rna
helicas
seem
individu
essenti
loss
one
dead
box
protein
yeast
complement
anoth
overexpress
famili
unwind
highli
structur
rna
might
reason
import
eukaryot
transcript
howev
direct
evid
role
rna
helicas
elus
transcrib
rna
rapidli
packag
ribonucleoprotein
complex
process
set
rna
helicas
play
role
remodel
evid
helicas
role
rna
wherea
other
serv
chaperon
rna
nucleu
cytoplasm
translat
mrna
cytoplasm
facilit
helicas
wherea
helicas
modul
stabil
dead
box
helicas
also
act
ribosom
biogenesi
regul
small
nucleolar
snorna
ribosom
rrna
rna
human
helicas
antivir
drug
target
correl
exist
genom
size
encod
helicas
strand
rna
although
virus
thought
function
need
helicas
case
larger
entiti
luxuri
selfencod
enzym
wherea
sizeconstrain
smaller
virus
adapt
use
cellular
helicas
gener
rna
virus
replic
cytoplasm
mostli
selfencod
helicas
wherea
replic
nucleu
often
util
cellular
helicas
consist
latter
notion
shown
two
recent
studi
coopt
activ
cellular
human
helicas
member
superfamili
requir
viral
rev
protein
export
unsplicedparti
splice
mrna
nucleu
cytoplasm
therefor
ad
list
potenti
treatment
target
enzym
revers
transcriptas
proteas
integras
viral
helicas
antivir
drug
target
potenti
helicas
antivir
drug
target
recent
unlik
retrovirus
two
human
virus
hsv
human
papillomaviru
hpv
physic
encod
helicas
hpv
member
superfamili
tabl
number
laboratori
develop
highthroughput
helicas
polymeras
screen
inhibitor
hpv
replic
date
success
clinic
drug
candid
deriv
effort
report
hsv
gene
encod
helicas
superfamili
form
heterotrimer
complex
respons
unwind
duplex
viral
dna
replic
fork
lay
okazaki
primer
elong
preclin
proof
concept
helicas
inhibitor
antivir
agent
obtain
use
highthroughput
screen
ht
thiazolylphenyl
dichloroanilino
purin
thiazolylsulphonamid
identifi
ht
inhibit
hsv
complex
optim
screen
hit
result
compound
inhibit
hsv
growth
cell
cultur
littl
cytotox
oral
activ
anim
model
hsv
mechanist
thiazolylphenylcontain
drug
seem
stabil
bind
polynucleotid
substrat
halt
catalyt
cycl
mechan
antivir
action
confirm
sever
group
independ
select
resist
virus
singl
point
mutat
dna
helicas
gene
class
compound
confirm
mechan
action
inhibitor
although
mutant
show
littl
reduct
replic
fit
compar
wildtyp
viru
cultur
fit
mutant
clinic
set
import
measur
fit
nonetheless
success
demonstr
date
possibl
develop
select
potent
inhibitor
viral
helicas
antivir
agent
preclin
set
hcv
helicas
antivir
drug
target
success
result
hsv
helicas
inhibitor
made
public
sever
year
mani
compani
start
screen
hcv
helicas
inhibitor
howev
time
widespread
optim
hcv
helicas
would
turn
good
target
antivir
drug
discoveri
bolster
success
exampl
antihiv
drug
design
structurebas
drug
design
effort
focus
find
inhibitor
three
essenti
viral
enzym
serin
rnadepend
rna
bifunct
protein
first
amino
acid
form
serin
proteinas
wherea
carboxytermin
amino
acid
form
helicas
biolog
standpoint
proteas
helicas
activ
coexist
vivo
either
could
serv
use
antihcv
target
helicas
polymeras
form
complex
host
viral
protein
creat
viral
replicas
multiprotein
order
hcv
multipli
negativestrand
rna
replic
intermedi
must
synthes
replicas
complex
use
incom
positivestrand
rna
infect
viru
templat
negativestrand
replic
intermedi
use
intermedi
templat
synthes
positivestrand
progeni
rna
packag
viral
capsid
posit
neg
rna
strand
complementari
hcv
helicas
thought
requir
strand
separ
addit
function
hcv
replic
might
includ
melt
highli
stabl
secondari
structur
known
present
hcv
rna
order
increas
translat
effici
polyprotein
increas
replic
rate
current
littl
known
crucial
interact
hcv
except
cofactor
interact
microscop
studi
indic
replicas
well
hcv
protein
congreg
er
form
membran
web
thought
cellular
factor
probabl
present
membraneassoci
complex
complex
futur
effort
map
interact
viral
protein
cellular
factor
import
success
drug
discoveri
consider
assay
design
form
protein
use
enzymat
screen
particularli
case
multidomain
multifunct
protein
nativ
state
helicas
domain
part
complex
also
contain
serin
proteas
domain
figur
show
crystal
structur
fulllength
coval
complex
comparison
three
helicas
domain
fulllength
protein
structur
helicas
domain
alon
shown
fig
reveal
structur
two
similar
posit
atp
molecul
shown
red
top
cleft
domain
posit
bound
oligonucleotid
crystal
structur
catalyt
domain
alon
reveal
presenc
proteas
domain
inhibit
access
site
proteas
domain
shown
fig
colour
blue
cofactor
green
locat
activ
site
indic
posit
peptidomimet
proteas
inhibitor
creat
use
structurebas
drug
design
show
presenc
helicas
domain
unlik
block
access
proteas
substrat
inhibitor
structur
studi
support
notion
absenc
replicas
protein
helicas
domain
larg
function
independ
proteas
domain
use
helicas
domain
alon
could
reason
choic
assay
format
howev
biochem
studi
compar
helicas
activ
fulllength
protein
truncat
helicas
domain
suggest
fulllength
domain
effici
unwind
subtl
differ
exist
mechan
unwind
fulllength
truncat
presenc
absenc
therefor
possibl
differ
inhibitor
might
score
posit
screen
use
differ
form
enzym
strategi
discov
inhibitor
consid
drug
design
helicas
one
begin
sever
gener
conceptu
strategi
helicas
multipl
enzymat
activ
function
domain
present
multipl
potenti
mechan
action
design
inhibitor
review
present
gener
descript
helicas
activ
suitabl
gener
reader
indepth
descript
found
detail
physic
kinet
analys
period
cycl
rna
unwind
paus
hcv
helicas
investig
sever
schemat
shown
fig
conform
activ
helicas
broadli
divid
open
close
complex
domain
transit
two
shown
fig
assay
use
identifi
smallmolecul
helicas
inhibitor
follow
effect
inhibit
ntpase
activ
direct
competit
ntp
competit
inhibit
nucleicacid
bind
inhibit
ntp
hydrolysi
ndp
releas
block
movement
domain
inhibit
process
coupl
ntp
hydrolysi
transloc
unwind
nucleic
acid
inhibit
unwind
steric
block
helicas
inhibit
unwind
review
ref
mechan
unwind
bind
assay
deploy
separ
categori
potenti
inhibitor
depict
fig
chang
physic
conform
helicas
inhibit
natur
rang
motion
requir
unwind
alter
interfac
domain
nonenzymat
mechan
action
new
helicas
inhibitor
could
includ
disrupt
turnov
protein
inhibit
crucial
interact
protein
replicas
complex
solut
crystal
structur
hcv
helicas
complex
oligonucleotid
well
mutagenesi
studi
identifi
key
residu
essenti
enzym
activ
transloc
rna
howev
consensu
mechan
unwind
three
differ
model
propos
three
differ
group
publish
crystal
structur
hcv
helicas
import
inhibit
function
essenti
helicas
activ
helicas
share
common
enzym
reaction
exampl
ntp
hydrolysi
transloc
mechan
action
might
difficult
avoid
possibl
hit
unintend
cellular
helicas
gener
unwant
side
effect
electrostat
analysi
hcv
helicas
show
activesit
nonactivesit
could
exploit
drug
design
although
might
tempt
inhibit
oligomer
inhibit
interact
small
molecul
could
difficult
interact
usual
multipl
point
contact
broad
surfac
area
block
one
contact
small
molecul
usual
suffici
block
bind
two
protein
kind
mechan
suitabl
target
antibodi
antibodi
mimic
likewis
target
addit
domain
uniqu
helicas
attempt
gain
specif
two
novel
conserv
motif
hcv
practic
unless
specif
assay
avail
function
known
associ
domain
approach
use
develop
reagent
bind
region
interest
recombin
human
rna
develop
bind
hcv
helicas
inhibit
hcv
helicas
activ
potenti
assay
laboratori
reli
simpl
unwind
assay
primari
ht
scintil
proxim
assay
spa
fluorometr
theoret
unwind
assay
increas
odd
find
inhibitor
inhibit
potenti
mechan
action
list
except
requir
cellular
environ
exampl
turnov
replicasecomplex
format
result
hit
exampl
lowpot
chemic
start
point
medicin
chemistri
optim
choic
stabl
dna
substrat
versu
natur
rna
substrat
avail
hcv
helicas
unwind
rna
dna
homo
heteroduplex
biochem
assay
detect
inhibitor
nucleicacid
bind
atpas
activ
run
ht
mode
primarili
use
elucid
mechan
action
inhibitor
reason
unwind
assay
could
also
find
inhibitor
caus
conform
chang
helicas
howev
screen
initi
hit
candid
inhibitor
usual
potent
use
sens
one
hope
evolv
potent
compound
empir
screen
hcv
helicas
candid
found
one
explan
dearth
result
could
nonpot
hit
simpli
could
bind
suffici
high
affin
helicas
inhibit
unwind
reaction
altern
unwind
assay
identifi
molecul
simpli
bind
helicas
alter
conform
accordingli
strategi
evolv
initi
binder
chang
conform
tighter
binder
also
inhibit
unwind
score
bind
conform
perturb
one
could
possibl
find
hit
score
unwind
effort
develop
hcv
inhibitor
three
major
hcv
enzymat
target
drug
discoveri
proteas
inhibitor
success
date
proof
concept
class
inhibitor
demonstr
boehring
ingelheim
vertex
pharmaceut
use
respect
compound
decreas
hcv
viral
load
patient
log
first
day
dose
patient
treat
hcv
viral
load
drop
infecti
unit
iu
per
ml
start
treatment
limit
detect
iu
per
ml
day
dose
sever
hcv
proteas
inhibitor
differ
compani
current
clinic
trial
speed
hcv
proteas
inhibitor
approach
clinic
remark
given
activ
site
enzym
notori
flat
featureless
addit
highthroughput
proteas
screen
larg
compound
librari
produc
good
hit
howev
possibl
use
hcv
proteas
substrat
cleavag
product
start
point
structurebas
design
creat
peptidomimet
inhibitor
clinic
develop
today
contrast
hcv
polymeras
highthroughput
assay
elong
gener
fruit
yield
divers
group
activesit
nonactivesit
inhibitor
differ
scaffold
avail
multipl
start
point
hcv
polymeras
inhibitor
mean
wealth
compani
preclin
inhibitor
shown
good
potenc
good
bioavail
contrast
hcv
proteas
inhibitor
number
polymeras
inhibitor
enter
clinic
fail
significantli
decreas
hcv
viral
load
patient
idenix
provid
proof
concept
activesit
polymeras
inhibitor
log
reduct
viral
titr
treat
patient
multipl
mechan
action
could
inhibit
hcv
helicas
mani
surpris
meagr
array
hit
helicas
screen
focus
chemic
mani
nucleicacid
binder
intercal
low
potenc
atpbind
site
success
target
kinas
gyras
inhibitor
bind
site
distinct
welldefin
pocket
contrast
weak
inhibitor
found
inhibit
hcv
bind
one
explan
might
hcv
helicas
ntpbind
site
interfac
domain
littl
specif
bind
ntp
primarili
phosphat
base
nucleotid
helicas
ntpbind
pocket
form
transient
domain
approach
domain
movement
result
hydrolysi
atp
concomit
open
separ
domain
domain
crucial
residu
helicas
activ
conserv
motif
array
insid
face
domain
potenti
targetbind
site
form
transient
two
domain
close
constant
movement
domain
open
close
configur
back
mean
enzym
like
often
yet
understand
necessari
principl
requir
inhibit
dynam
protein
system
hard
imagin
develop
hcv
helicas
inhibitor
clinic
use
slow
enzym
move
target
undergo
signific
transient
conform
chang
requir
coupl
ntp
hydrolysi
degre
movement
illustr
fig
superimposit
eight
independ
hcv
helicas
crystal
structur
fig
superimposit
four
eight
independ
hcv
helicas
structur
domain
rel
rigid
respect
trace
lie
top
wherea
domain
larg
freedom
motion
indic
fig
silver
ball
identifi
singl
carbon
atom
domain
final
smallmolecul
drug
design
requir
reason
start
point
whether
substrat
mimic
hit
screen
obviou
hcv
helicas
crystal
structur
gate
keeper
residu
crucial
bind
unwind
nucleic
acid
form
bind
pocket
suitabl
structurebas
inhibitor
design
conclud
remark
global
infect
million
individu
hcv
estim
million
carrier
cell
virus
requir
helicas
function
necessarili
nucleicacid
replic
requir
longterm
treatment
regimen
hiv
allow
gener
drugresist
mutat
cours
therapi
minim
possibl
gener
resist
target
cellular
enzym
requir
could
viabl
option
mani
nonantiinfect
drug
therapi
target
cellular
enzym
angiotensinconvert
enzym
ace
treat
hypertens
congest
heart
failur
myocardi
infarct
endotheli
dysfunct
renal
potenti
offtargetinduc
cytotox
signific
irrespect
whether
one
target
cellular
viral
helicas
similar
structur
function
howev
recent
character
requir
helicas
revdepend
gene
express
could
new
mean
treat
without
gener
drugresist
virus
laboratori
ktj
preliminari
evid
found
ringexpand
nucleosid
analogu
previous
use
success
ntpasehelicas
inhibitor
west
nile
substanti
activ
cultur
cell
noncytotox
dose
hsv
inhibitor
offer
proof
principl
viral
helicas
complex
specif
differenti
select
inhibit
among
pool
relat
cellular
helicas
cellbas
experi
infecti
anim
model
without
signific
cytotox
although
conserv
helicas
motif
within
helicas
similar
individu
helicas
wide
diverg
code
sequenc
rais
possibl
individu
protein
could
target
specif
knowledgebas
manner
highlight
tabl
emerg
pictur
virus
either
encod
helicas
use
cellular
helicas
replic
exampl
poxvirus
papovavirus
pathogen
rna
virus
west
nile
viru
sever
acut
respiratori
syndrom
sar
coronaviru
dengu
fever
viru
encod
viral
helicas
could
potenti
futur
antivir
target
regrett
rare
drug
candid
mention
review
current
clinic
use
candid
compound
viral
helicas
cumul
success
virusencod
helicas
like
preced
effect
drug
target
cellular
helicas
use
virus
